SUMMARY Osteogenesis imperfecta, Ehlers-Danlos syndrome, and Marfan syndrome form a group of genetic disorders of connective tissue. These disorders exhibit remarkable clinical heterogeneity which reflects their underlying biochemical and molecular differences. Defects in collagen types I and III have been found in all three syndromes.
The term 'collagen disease' should be confined to a small group of disorders caused by structural or metabolic defects of collagen. Our understanding of the pathobiology of the genetic collagen disorders has been slow in its evolution, particularly when compared to other genetic disorders like the haemoglobinopathies. This is partly due to the biological complexity of the connective tissues and partly to our limited knowledge of the various structural, functional, and genetic features of these proteins. To a certain extent knowledge of the latter has been increased by several fundamental findings, such as the discovery of the tissue heterogeneity of collagens, the elucidation of the numerous biosynthetic steps leading to collagen fibrillogenesis, and last, but not least important, by the isolation and characterisation of several human collagen genes. In this review we will cover basic aspects of the biochemistry and molecular biology of the human collagen system and discuss findings from some well documented variants of heritable disorders of collagen. We will also attempt to relate this basic information to the practice of clinical genetics.
Collagen: the biochemistry Tissue specific expression of different collagen types is partly responsible for the unique physical properties of the various connective tissues. To date, at least 10 different collagen types, whose subunits are Received for publication 9 May 1986. Accepted for publication 22 May 1986. encoded by approximately 20 distinct genes, have been identified.' 2 While very little is known about the contribution of most of these proteins to the structural integrity of the extracellular matrix, this role is quite obvious for the so-called fibrillar collagens, types I, II, and III. The designation fibrillar is derived from the type of supramolecular aggregates (fibrils) they form in several connective tissues, such as tendon, ligaments, skin, cartilage, and bone.3 Four distinct genes encode the subunits of the three fibrillar collagens (table) . Typically, a fibrillar collagen is synthesised as a precursor molecule (preprocollagen) which comprises a short signal peptide, two terminal (carboxy and amino) propeptides, and a central a chain segment (fig 1) . The structure of the central segment, also known as the triple helical domain, is characterised by the presence of a glycine residue in every third position. remains to be elucidated, as does the evolutionary reason that determined the final number of duplications. To some extent the study of collagen mutations resulting in pathological phenotypes has shed new light on these and other structural as well as biosynthetic features of the fibrillar collagens.
Connective tissue disorders include a large variety of syndromes with heterogeneous and sometimes overlapping modes of expression. Abnormalities in the structure and in the biosynthesis of the fibrillar collagens have been associated with osteogenesis imperfecta (01), Marfan syndrome, Ehlers-Danlos syndromes (EDS), and possibly the chondrodystrophies. In the following sections we will attempt to discuss some mutations of collagen types I and III in relation to specific clinical phenotypes and show how genetic linkage can be used in the study of these disorders.
Osteogenesis imperfecta
The term osteogenesis imperfecta describes a group of disorders which are highly heterogeneous in their phenotypic manifestations.'1 Bone fragility is the cardinal clinical manifestation of the 01 syndromes.
In addition, short stature, joint laxity, easy bruising, blue sclerae, presenile hearing loss, and dentinogenesis imperfecta may also be present. This phenotypic diversity has prompted numerous attempts at classification, the most recent and widely accepted one having been proposed by Sillence et OI type III is also heterogeneous and is clinically characterised by significant bone fragility with fractures frequently occurring in utero, short stature, and usually significant skeletal deformity, dentinogenesis imperfecta, hearing loss, and blue sclerae. In the majority of families studied, the proband is the only affected subject. Autosomal recessive inheritance has also been suggested" and documented.26 Biochemical studies in fibroblasts derived from a patient with 01 type III showed secretion of type I procollagen molecules consisting of proa2(I) chains intracellularly.27 Northern blot hybridisation showed that the patient's fibroblasts contained normal levels of proa2(I) mRNA, efficiently translatable in a heterologous cell free system.28 A combination of nuclease S1 mapping and the cloning and sequencing of the mutant allele showed a four base pair frame shift deletion resulting in a complete alteration of the codon phase for the last 34 amino acids of the C-propeptide of the proa2(I) chain.26 29 In addition, the deletion eliminated the last cysteine in the C-propeptide. This observation dramatically demonstrates the importance of the interchain disulphide bonds in the formation of the triple helix. The mutation was inherited as an autosomal recessive trait from the parents, who were third cousins and phenotypically normal.
OI type IV is inherited as an autosomal dominant trait and is characterised by mild to moderate bone fragility, usually postnatal onset of fractures, short stature, white sclerae, hearing loss, and dentinogenesis imperfecta. " 
